The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
Open accessAbstract
Avibactam is a non-β-lactam β-lactamase inhibitor with a spectrum of activity that includes β-lactamase enzymes of classes A, C, and selected D examples. In this work acylation and deacylation rates were measured against the clinically important enzymes CTX-M-15, KPC-2, Enterobacter cloacae AmpC, Pseudomonas aeruginosa AmpC, OXA-10, and OXA-48. The efficiency of acylation (k2/Ki) varied across the enzyme spectrum, from 1.1 × 101 m−1s−1 for OXA-10 to 1.0 × 105 for CTX-M-15. Inhibition of OXA-10 was shown to follow the covalent reversible mechanism, and the acylated OXA-10 displayed the longest residence time for deacylation, with a half-life of greater than 5 days. Across multiple enzymes, acyl enzyme stability was assessed by mass spectrometry. These inhibited enzyme forms were stable to rearrangement or hydrolysis, with the exception of KPC-2. KPC-2 displayed a slow hydrolytic route that involved fragmentation of the acyl-avibactam complex. The identity of released degradation products was investigated, and a possible mechanism for the slow deacylation from KPC-2 is proposed.Background: Avibactam is a β-lactamase inhibitor with a broad spectrum of activity.Results: Kinetic parameters of inhibition as well as acyl enzyme stability are reported against six clinically relevant enzymes.Conclusion: Inhibition efficiency is highest against class A, then class C, and then class D.Significance: These base-line inhibition values across enzyme classes provide the foundation for future structural and mechanistic enzymology experiments. Avibactam is a non-β-lactam β-lactamase inhibitor with a spectrum of activity that includes β-lactamase enzymes of classes A, C, and selected D examples. In this work acylation and deacylation rates were measured against the clinically important enzymes CTX-M-15, KPC-2, Enterobacter cloacae AmpC, Pseudomonas aeruginosa AmpC, OXA-10, and OXA-48. The efficiency of acylation (k2/Ki) varied across the enzyme spectrum, from 1.1 × 101 m−1s−1 for OXA-10 to 1.0 × 105 for CTX-M-15. Inhibition of OXA-10 was shown to follow the covalent reversible mechanism, and the acylated OXA-10 displayed the longest residence time for deacylation, with a half-life of greater than 5 days. Across multiple enzymes, acyl enzyme stability was assessed by mass spectrometry. These inhibited enzyme forms were stable to rearrangement or hydrolysis, with the exception of KPC-2. KPC-2 displayed a slow hydrolytic route that involved fragmentation of the acyl-avibactam complex. The identity of released degradation products was investigated, and a possible mechanism for the slow deacylation from KPC-2 is proposed. Background: Avibactam is a β-lactamase inhibitor with a broad spectrum of activity. Results: Kinetic parameters of inhibition as well as acyl enzyme stability are reported against six clinically relevant enzymes. Conclusion: Inhibition efficiency is highest against class A, then class C, and then class D. Significance: These base-line inhibition values across enzyme classes provide the foundation for future structural and mechanistic enzymology experiments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367
Three Decades of β-Lactamase Inhibitors
Drawz, S. M., & Bonomo, R. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00037-09 · Cited by 1,709
Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention
Gupta, N., Limbago, B. M., Patel, J. B., & Kallen, A. J. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir202 · Cited by 1,033
Cited by
β-Lactams and β-Lactamase Inhibitors: An Overview
Bush, K., & Bradford, P. A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025247 · Cited by 1,412
β-Lactamases and β-Lactamase Inhibitors in the 21st Century
Tooke, C. L., Hinchliffe, P., Bragginton, E. C., Colenso, C. K., Hirvonen, V. H. A., Takebayashi, Y., & Spencer, J. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.04.002 · Cited by 1,016
Epidemiology of β-Lactamase-Producing Pathogens
Bush, K., & Bradford, P. A. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00047-19 · Cited by 938
Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections
Shirley, M. (2018) · Drugs · doi:10.1007/s40265-018-0902-x · Cited by 371
Lomovskaya, O., Sun, D., Rubio-Aparicio, D., Nelson, K., Tsivkovski, R., Griffith, D. C., & Dudley, M. N. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01443-17 · Cited by 353
Metadata
- Authors
- Ehmann, D. E., Jahić, H., Ross, P. L., Gu, R.-F., Hu, J., Durand-Réville, T. F., Lahiri, S., Thresher, J., Livchak, S., Gao, N., Palmer, T., Walkup, G. K., & Fisher, S. L.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 288
- Issue
- 39
- Pages
- 27960-27971
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2091219913
- Cited by
- 372
- References
- 3
- FWCI
- 11.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases. https://app.cochat.ai/papers/10.1074/jbc.m113.485979
- The paper
- Ehmann, D. E., Jahić, H., Ross, P. L., Gu, R.-F., Hu, J., Durand-Réville, T. F., Lahiri, S., Thresher, J., Livchak, S., Gao, N., Palmer, T., Walkup, G. K., & Fisher, S. L. (2013). Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.m113.485979
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.